Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Switzerland-based generic drug maker Sandoz said on Monday that it has filed an antitrust lawsuit against Amgen, Inc, (AMGN) ...

Sandoz (SDZNY) announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the ...

All proposals of Board of Directors approvedGilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

The health sector faces upheavals as Sandoz files an antitrust lawsuit against Amgen over arthritis drug market ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sandoz ...